About Eloxx

Committed to Treating Rare and
Ultra-Rare Genetic Diseases

Eloxx is a clinical-stage biopharmaceutical company committed to treating patients suffering from rare and ultra-rare diseases caused by Premature Termination Codon (PTC) nonsense mutations.

The company is led by a management team experienced in the development of rare disease therapeutics. All of us at Eloxx share the same goal: to bring safe and effective therapies to the children and adults who need them, as quickly as possible

Management

Dr. Silvia Noiman has over 20 years of experience as an entrepreneur and executive in the biopharmaceuticals industry, including serving as venture partner at Pontifax Venture Capital. Dr. Noiman founded and serves as a board member of many of the Pontifax Group’s portfolio companies, including cCAM Biotherapeutics Ltd. and Quiet Therapeutics Ltd. She was also founder and Senior Vice President of Predix Pharmaceuticals Ltd., bringing a small early-stage drug discovery company from inception to a publicly traded multi-product company (NASDAQ, EPIX). Under Dr. Noiman’s leadership, the company progressed four discovery programs to clinical trials and formed significant big pharma partnerships. Prior to founding Predix, she was engaged in large-scale entrepreneurial activities in the biotech industry in Israel. Dr. Noiman holds a PhD in Molecular Biology from Tel Aviv University and did a post-doc at the Weizmann Institute of Science. Dr.Noiman has published numerous papers and holds several patents.

Dr. Tuvia has been developing drugs since the 1990s. Prior to joining Eloxx, Dr. Tuvia served as VP of Preclinical research at Chiasma Pharmaceuticals Ltd. (NASDAQ:CHMA), where he headed all preclinical development and pharmacology of oral octreotide from the initial early proof of concept preclinical phase through licensing of the project to Roche. Previously, he worked in several biotech companies where he focused on discovery and development of new drugs and technologies. Dr. Tuvia conducted postdoctoral research at Duke University Medical Center, in Durham, North Carolina. He earned his PhD with Distinction at the Sackler School of Medicine, Tel-Aviv University, Israel. Dr. Tuvia has published approximately 20 peer-reviewed scientific articles and holds a number of patents.

Dr. Huertas has been active in the pharmaceutical industry for nearly 20 years and is experienced in research, development, medical affairs, and regulatory affairs concerning therapeutics for human genetic and metabolic diseases. Dr. Huertas’ last position was with Precision Medicine as Clinical Lead and Head of Precision Medicine for Rare Diseases at Pfizer Worldwide Research & Development. Dr. Huertas has extensive experience dealing with and participating in negotiations with regulatory authorities in the US (FDA), EU (EMA), Japan (PMDA), and throughout Latin America. He led the clinical team that filed for approval of and registered Fabrazyme (agalsidase beta) in the United States, Europe, and Japan. Dr. Huertas is a graduate of Stanford University (MS, Biochemistry), Harvard University (PhD, Cell and Developmental Biology), the Program in Health Sciences and Technology between Harvard Medical School and the Massachusetts Institute of Technology (MD), and the Sloan School of Management at the Massachusetts Institute of Technology (MS, Management). He trained in Internal Medicine, Rheumatology, and Palliative Care at Massachusetts General Hospital.

Dr. Pelled brings to Eloxx over 15 years of experience in the biotech industry. Prior to joining Eloxx, he headed the preclinical research and development at Chiasma Pharmaceuticals Ltd. (NASDAQ:CHMA), a drug company that redevelops poorly-absorbed small molecules into oral drugs, and at NiTi Surgical Solutions, a medical device company that focused on implants for gastrointestinal surgery. Prior to NiTi, he was responsible for clinical research and for the developing of new molecules in the medical food company, Enzymotec (NASDAQ:ENZY), where he served as the Director of Clinical Studies and as the CTO. Dr. Pelled has published over 25 original papers in peer-reviewed journals and he holds 15 patents. He received his PhD in Biochemistry from the Weizmann Institute of Science, and obtained BSc and MSc degrees in Chemistry and Clinical Biochemistry from the Tel-Aviv University.

Dr. Reed has been in the pharmaceutical industry more than 15 years, mainly leading technical and research aspects of investigational/commercial API manufacturing and analytics. In his last position, Dr. Reed served as the Director of API at TESARO. Previously, Dr. Reed was the Associate Director and Director, Process Chemistry R&D at Sunovion Pharmaceuticals and ArQule Inc., respectively, where he was responsible for all aspects of API research, manufacture, and analytical development. Prior to joining ArQule Inc., he served as a Scientist II at Millennium Pharmaceuticals and as a Senior Research Scientist at AMRI (Albany, NY). Dr. Reed holds a PhD from the University of New Hampshire, Durham, USA and a BSc from Saint Michael’s College Colchester Park, Winooski, VT, in Chemistry. He did his postdoctoral research at the University of Connecticut, in collaboration with P & G Pharmaceuticals and was certified as a Project Management Professional (PMP).

Board of Directors

Dr. Robert Heft brings more than 30 years of biopharmaceutical executive leadership experience to Eloxx. He served as the President and CEO of Enobia Pharma Inc. In February 2012 he sold Enobia to Alexion Pharmaceuticals Inc. for USD 1.1 billion, the largest-ever sale of a private, pre-commercial biopharmaceutical company. Dr. Heft held several senior positions with BioMarin Pharmaceutical Inc. following BioMarin’s acquisition of IBEX Pharmaceuticals in 2001. Dr. Heft founded IBEX in 1986 and served as its President, Chief Scientist, and board member. In addition to Eloxx, Dr. Heft currently serves on the boards of Zingenix Ltd., VisionGate Inc., Lumos Pharma Inc., Clementia Pharmaceuticals Inc., and Ra Pharma Inc. He also serves on the Advisory Board of Sectoral Asset Management. Dr. Heft has a PhD from the Massachusetts Institute of Technology in Genetic Engineering and Radiological sciences. He has received several awards for his work.

Dr. Silvia Noiman has over 20 years of experience as an entrepreneur and executive in the biopharmaceuticals industry, including serving as venture partner at Pontifax Venture Capital. Dr. Noiman founded and serves as a board member of many of the Pontifax Group’s portfolio companies, including cCAM Biotherapeutics Ltd. and Quiet Therapeutics Ltd. She was also founder and Senior Vice President of Predix Pharmaceuticals Ltd., bringing a small early-stage drug discovery company from inception to a publicly traded multi-product company (NASDAQ, EPIX). Under Dr. Noiman’s leadership, the company progressed four discovery programs to clinical trials and formed significant big pharma partnerships. Prior to founding Predix, she was engaged in large-scale entrepreneurial activities in the biotech industry in Israel. Dr. Noiman holds a PhD in Molecular Biology from Tel Aviv University and did a post-doc at the Weizmann Institute of Science. Dr.Noiman has published numerous papers and holds several patents.

Mr. Veinrib has extensive managerial experience in the internet, digital, and communication fields. He worked as a VP at Elron, as well as serving as Executive Assistant to the President and CEO at Discount Investment Corporation (DIC). Mr. Veinrib previously served as director of NetVision and Nana10 as well as other companies within the DIC group. Mr. Veinrib holds a B.A. in Economics from Tel Aviv University.

Ran is a managing partner and co-founder of The Pontifax Group. The fund is running more than 45 portfolio companies all around the globe. Prior to joining Pontifax, he was a partner at Israel’s largest business intelligence and strategic consulting firm. Ran’s work revolves around constant and active involvement in companies, providing them with strategic and business development oversight. Ran serves as a board member on many of Pontifax’s portfolio companies, including Kite pharma (public co.), Keros (as chairman), UroGen, cCAM Biotherapeutics (bought by Merck), Nutrinia Ltd, Novellus Ltd, Quiet Therapeutics and other bio-pharma companies. He also chaired Ocon Medical, NasVax and ran Biomedix Ltd and Spearhead Ltd in the past.

Tomer is the co-founder and Chief Executive Officer of Pontifax – The fund is running more than 45 portfolio companies around the globe and serves as an active board member of many of the funds’ portfolio companies, assuming a special responsibility for strategic planning. Among other positions, Tomer serves as the Chairman of Check-Cap and is a board member at Macrocure and V-Wave. During the 10 years prior to establishing Pontifax, he held senior management  positions at top  Israeli financial institutions, playing a key role in investing in, nurturing and managing technology driven startups. Tomer holds a B.A. in Economics from Harvard University and a J.D. from Harvard Law School.

Dr. Tuvia has been developing drugs since the 1990s. Prior to joining Eloxx, Dr. Tuvia served as VP of Preclinical research at Chiasma Pharmaceuticals Ltd. (NASDAQ:CHMA), where he headed all preclinical development and pharmacology of oral octreotide from the initial early proof of concept preclinical phase through licensing of the project to Roche. Previously, he worked in several biotech companies where he focused on discovery and development of new drugs and technologies. Dr. Tuvia conducted postdoctoral research at Duke University Medical Center, in Durham, North Carolina. He earned his PhD with Distinction at the Sackler School of Medicine, Tel-Aviv University, Israel. Dr. Tuvia has published approximately 20 peer-reviewed scientific articles and holds a number of patents.